Shares rose 8.5% following the quarter as investors responded positively to the confirmation of the medical cannabis rescheduling to Schedule III and the clear path toward interstate commerce and export opportunities, which expanded the company’s addressable market. Despite adjusted EBITDA losses and margin pressure, the market focused on the strategic upside from regulatory progress and operational expansion.